Overview
Lipoprotein a is a type of low-density lipoprotein that plays a significant role in cardiovascular risk assessment. It consists of a lipid core similar to LDL, with apolipoprotein B bound to a unique glycoprotein called apolipoprotein a through a disulfide bond. Elevated levels of lipoprotein a are recognized as an independent risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis. High concentrations contribute to atherosclerosis and thrombosis by influencing inflammation, endothelial dysfunction, oxidative stress, and impaired fibrinolysis. These levels are largely genetically determined and remain relatively stable throughout life.
Symptoms
It itself does not produce direct clinical symptoms. However, elevated levels are strongly associated with cardiovascular conditions that may present with symptoms such as chest pain, shortness of breath, reduced exercise tolerance, or neurological deficits related to stroke. Individuals with high lipoprotein a may experience premature cardiovascular events, including heart attack or stroke, often without significant abnormalities in routine lipid parameters.
Causes
Raised lipoprotein a levels are most commonly due to genetic factors, particularly variations in the LPA gene, and often run in families. Certain ethnic populations, especially individuals of African descent, tend to have higher baseline levels. It may also be elevated in familial hypercholesterolemia, chronic kidney disease, nephrotic syndrome, and some liver or metabolic disorders. Hormonal influences such as pregnancy, thyroid disorders, and hormone replacement therapy can affect levels. Dietary changes, particularly replacement of saturated fats with carbohydrates or unsaturated fats, may cause a modest increase in lipoprotein a in some individuals. Reduced levels may be seen due to genetic isoforms, severe liver dysfunction, remission of nephrotic syndrome, or with the use of certain medications such as niacin or PCSK9 inhibitors.
Risk Factors
High lipoprotein a is a major risk factor for premature atherosclerotic cardiovascular disease, stroke, and calcific aortic valve stenosis. Risk is further increased in individuals with a family history of early cardiovascular disease, familial hypercholesterolemia, or recurrent unexplained cardiovascular events. Borderline or intermediate levels may still contribute to cardiovascular risk when combined with other factors such as hypertension, diabetes, smoking, or elevated LDL cholesterol. Because levels are genetically driven, lifestyle modification alone has a limited impact on reducing lipoprotein a.
Prevention
There are no specific lifestyle measures that reliably lower lipoprotein a levels, but early identification helps guide preventive cardiovascular strategies. Measurement is recommended in individuals with a family history of premature cardiovascular disease, unexplained early events, or high risk despite controlled LDL cholesterol. Prevention focuses on aggressive management of modifiable risk factors such as LDL cholesterol, blood pressure, diabetes, and smoking cessation. Proper sample collection, handling, and interpretation of results ensure accurate risk assessment and support timely clinical decision-making to reduce long-term cardiovascular complications.
